Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-02-12 5:16 pm Purchase | 13G | Forma Therapeutics Holdings Inc. FMTX | Lilly Ventures Fund I LLC | 2,404,069 5.200% | 2,404,069 (New Position) | View |
| 2021-02-12 5:08 pm Sale | 13G | Surface Oncology Inc. SURF | Lilly Ventures Fund I LLC | 3,447,817 8.500% | -36,801 (-1.06%) | View |
| 2021-02-12 4:59 pm Sale | 13G | Spyre Therapeutics Inc. SYRE | Lilly Ventures Fund I LLC | 2,568,543 5.400% | -80,666 (-3.04%) | View |
| 2020-06-08 4:04 pm Sale | 13D | PROTAGONIST THERAPEUTICS INC C PTGX | Lilly Ventures Fund I LLC | 1,559,060 4.500% | -540,422 (-25.74%) | View |
| 2020-02-13 4:17 pm Sale | 13G | SUTRO BIOPHARMA INC STRO | Lilly Ventures Fund I LLC | 968,161 4.200% | -572,652 (-37.17%) | View |
| 2020-02-13 4:17 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | Lilly Ventures Fund I LLC | 2,649,209 9.100% | 16,400 (+0.62%) | View |
| 2020-02-13 4:17 pm Purchase | 13G | Surface Oncology Inc. SURF | Lilly Ventures Fund I LLC | 3,484,618 12.500% | 30,741 (+0.89%) | View |